title: Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men.
abstract: Cholecystokinin (CCK), peptide YY (PYY), and ghrelin have been proposed to act as satiety hormones. CCK and PYY are stimulated during meal intake by the presence of nutrients in the small intestine, especially fat, whereas ghrelin is inhibited by eating. The sequence of events (fat intake followed by fat hydrolysis and CCK release) suggests that this process is crucial for triggering the effects. The aim of this study was therefore to investigate whether CCK mediated the effect of intraduodenal (ID) fat on ghrelin secretion and PYY release via CCK-1 receptors. Thirty-six male volunteers were studied in three consecutive, randomized, double-blind, cross-over studies: 1) 12 subjects received an ID fat infusion with or without 120 mg orlistat, an irreversible inhibitor of gastrointestinal lipases, compared with vehicle; 2) 12 subjects received ID long-chain fatty acids (LCF), ID medium-chain fatty acids (MCF), or ID vehicle; and 3) 12 subjects received ID LCF with and without the CCK-1 receptor antagonist dexloxiglumide (Dexlox) or ID vehicle plus intravenous saline (placebo). ID infusions were given for 180 min. The effects of these treatments on ghrelin concentrations and PYY release were quantified. Plasma hormone concentrations were measured in regular intervals by specific RIA systems. We found the following results. 1) ID fat induced a significant inhibition in ghrelin levels (P < 0.01) and a significant increase in PYY concentrations (P < 0.004). Inhibition of fat hydrolysis by orlistat abolished both effects. 2) LCF significantly inhibited ghrelin levels (P < 0.02) and stimulated PYY release (P < 0.008), whereas MCF were ineffective compared with controls. 3) Dexlox administration abolished the effect of LCF on ghrelin and on PYY. ID fat or LCF significantly stimulated plasma CCK (P < 0.006 and P < 0.004) compared with saline. MCF did not stimulate plasma CCK release. In summary, fat hydrolysis is essential to induce effects on ghrelin and PYY through the generation of LCF, whereas MCF are ineffective. Furthermore, LCF stimulated plasma CCK release, suggesting that peripheral CCK is the mediator of these actions. The CCK-1 receptor antagonist Dexlox abolished the effect of ID LCF, on both ghrelin and PYY. Generation of LCF through hydrolysis of fat is a critical step for fat-induced inhibition of ghrelin and stimulation of PYY in humans; the signal is mediated via CCK release and CCK-1 receptors.
authors.affiliation: Division of Gastroenterology, University Hospital, CH-4031 Basel, Switzerland.
authors.forename: Lukas
authors.initials: L
authors.lastname: Degen
authors.forename: Juergen
authors.initials: J
authors.lastname: Drewe
authors.forename: Franziska
authors.initials: F
authors.lastname: Piccoli
authors.forename: Karin
authors.initials: K
authors.lastname: Gräni
authors.forename: Sibylle
authors.initials: S
authors.lastname: Oesch
authors.forename: Raluca
authors.initials: R
authors.lastname: Bunea
authors.forename: Massimo
authors.initials: M
authors.lastname: D'Amato
authors.forename: Christoph
authors.initials: C
authors.lastname: Beglinger
mesh_terms: D000328:Adult; D002210:Caprylates / Q000008:administration & dosage / Q000737:chemistry; D002766:Cholecystokinin / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005227:Fatty Acids / Q000008:administration & dosage / Q000737:chemistry / Q000502:physiology; D054439:Ghrelin; D006801:Humans; D007262:Infusions, Intravenous; D007783:Lactones / Q000008:administration & dosage / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors; D008297:Male; D019301:Oleic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000502:physiology; D000069463:Olive Oil; D000077403:Orlistat; D010421:Pentanoic Acids / Q000008:administration & dosage / Q000494:pharmacology; D036361:Peptide Hormones / Q000097:blood / Q000378:metabolism*; D019894:Peptide YY / Q000097:blood / Q000378:metabolism*; D010938:Plant Oils / Q000008:administration & dosage; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D013997:Time Factors
chemical_list: D002210:Caprylates; D004791:Enzyme Inhibitors; D005227:Fatty Acids; D054439:Ghrelin; D007783:Lactones; D000069463:Olive Oil; D010421:Pentanoic Acids; D036361:Peptide Hormones; D010938:Plant Oils; D011949:Receptors, Cholecystokinin; D019894:Peptide YY; D019301:Oleic Acid; C103490:dexloxiglumide; D002766:Cholecystokinin; D000077403:Orlistat; D008049:Lipase; C031492:octanoic acid